Paladin Labs Inc.  

(Public, TSE:PLB)   Watch this stock  
Find more results for TSE: PLB
0.0000
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 45.56 - 151.83
Open     -
Vol / Avg. 0.00/53,394.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 2.41
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 19.21% 27.76%
Operating margin 24.66% 32.02%
EBITD margin - 36.44%
Return on average assets 8.92% 11.64%
Return on average equity 13.41% 16.96%
Employees 126 -
CDP Score - -

Address

Suite 600, 100 Blvd. Alexis Nihon
ST.LAURENT, QC H4M 2P2
Canada
+1-514-3401112 (Phone)
+1-514-3444675 (Fax)

Website links

Description

Paladin Labs Inc. is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. The Company�s product portfolio includes Tridural, Abstral and Trelstar. Tridural is a once-a-day tramadol product indicated as a first-line therapy for adults with moderate pain requiring several days or more of treatment. Abstral is a sublingual tablet used for the management of breakthrough cancer pain in patients who are already tolerant to other opioid analgesics. Trelstar is an injectable, luteinizing hormone releasing hormone agonist indicated for the palliative treatment of prostate cancer and endometriosis. In July 2013, the Company became the sole holder of Allon Therapeutics Inc. In September 2013, Blackstar Group SE announced that it has sold remaining 13.4% interests in Litha Healthcare Group Limited (Litha) to Paladin Labs Inc. Effective January 1, 2014, Paladin Labs Inc. acquired Triton Pharma Inc.